Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in adult idiopathic inflammatory myopathy
NCT04208464Phase 2Completed
- Sponsor
- The University of Manchester
- Start
- Oct 2021
- Primary completion
- Sep 2023
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of baricitinib in idiopathic inflammatory myopathy (IIM), sponsored by The University of Manchester. Started Oct 2021; status: completed.
02
Drugs
baricitinib
03
Conditions
idiopathic inflammatory myopathy (IIM)
Beyond the preview
Go deeper on NCT04208464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04208464.